General
Preferred name
OROXYLIN A
Synonyms
6-Methoxybaicalein ()
Baicalein 6-methyl ether ()
P&D ID
PD040563
CAS
480-11-5
Tags
available
natural product
nuisance
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Oroxylin A is an active flavonoid compound with strong anti-cancer effects. Oroxylin A inhibits the IL-6/STAT3 pathway and NF-¦ÊB signaling, inhibits cell proliferation and induces apoptosis. Oroxylin A inhibits colitis-related carcinogenesis[1][2][3][4][5].
PRICE 70
DESCRIPTION 1. Oroxylin A (Baicalein 6-methyl ether) has various anti-tumor effects including apoptosis, cell cycle arrest, drug-resistant reversion. 2. Oroxylin A possesses abilities of inhibiting the ATRA-induced IL-6 production via modulation of LAP/LIP/CHOP in leukemia cell lines, which could providing a therapeutic strategy for RAS. 3. Oroxylin A inhibits UCP2s triggers the MPTP opening, and promotes the apoptosis in CaCo-2 cells; uncoupling protein 2 plays a key role in mitochondrial apoptotic pathway. 4. Oroxylin A inhibits N1ICD translocating to the nucleus and binding to epithelial-mesenchymal transition-related transcription factor Snail, thus suppressing the invasion and migration of MCF-7 cells. 5. Oroxylin A improves the sensitivity of K562/ADM cells by increasing apoptosis in leukemic cells and decreasing the expression of CXCR4 and PI3K/Akt/NF-??B pathway, and probably served as a most promising agent for CML treatment.
DESCRIPTION Oroxylin A is an active phytochemical that can be isolated from the Chinese herb Huang-Chi (Astragalus mongholicus; Mongolian milkvetch in English) and other herbal plants such as Scutellaria baicalensis. It has demonstrated anti-inflammatory , anti-infection and anti-tumour activities in experimental models, which suggests therapeutic potential in human diseases . (GtoPdb)
DESCRIPTION 1. Oroxylin A (Baicalein 6-methyl ether) has various anti-tumor effects including apoptosis, cell cycle arrest, drug-resistant reversion. 2. Oroxylin A possesses abilities of inhibiting the ATRA-induced IL-6 production via modulation of LAP/LIP/CHOP in leukemia cell lines, which could providing a therapeutic strategy for RAS. 3. Oroxylin A inhibits UCP2s triggers the MPTP opening, and promotes the apoptosis in CaCo-2 cells; uncoupling protein 2 plays a key role in mitochondrial apoptotic pathway. 4. Oroxylin A inhibits N1ICD translocating to the nucleus and binding to epithelial-mesenchymal transition-related transcription factor Snail, thus suppressing the invasion and migration of MCF-7 cells. 5. Oroxylin A improves the sensitivity of K562/ADM cells by increasing apoptosis in leukemic cells and decreasing the expression of CXCR4 and PI3K/Akt/NF-κB pathway, and probably served as a most promising agent for CML treatment. (TargetMol Bioactive Compound Library)
Cell lines
5
Organisms
1
Compound Sets
7
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
Guide to Pharmacology
MedChem Express Bioactive Compound Library
Nuisance compounds in cellular assays
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
External IDs
32
Properties
(calculated by RDKit )
Molecular Weight
284.07
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
2
Rotatable Bonds
2
Ring Count
3
Aromatic Ring Count
3
cLogP
2.88
TPSA
79.9
Fraction CSP3
0.06
Chiral centers
0.0
Largest ring
6.0
QED
0.76
Structural alerts
1
Nonspecific/NOS
Flavonoid
Nuisance compounds
Custom attributes
(extracted from source data)
MOA
Autophagy
HIF/HIF Prolyl-Hydroxylase
Pathway
Chromatin/Epigenetic
Metabolism
Microbiology/virology
Anti-infection
Metabolic Enzyme/Protease
Target
Virus Protease
Immunology & Inflammation related
Source data